ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

ADPT · CIK 1478320 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$277M
20192025
Net Income−$59M
20192025
Operating CF−$46M
20192025
Free Cash Flow−$49M
20192025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Revenue$0.3B$0.2B$0.2B$0.2B$0.2B$0.1B$0.1B
Cost of Revenue$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
Gross Profit———————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense———————
Operating Income$-0.1B$-0.2B$-0.2B$-0.2B$-0.2B$-0.2B$-0.1B
Net Income$-0.1B$-0.2B$-0.2B$-0.2B$-0.2B$-0.1B$-0.1B
EPS (Basic)$-0.39$-1.08$-1.56$-1.40———
EPS (Diluted)$-0.39$-1.08$-1.56$-1.40———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Total Assets$0.5B$0.5B$0.7B$0.9B$0.9B$1.1B$0.9B
Current Assets$0.3B$0.3B$0.4B$0.6B$0.4B$0.7B$0.6B
Cash & Equivalents$0.1B$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B
Total Liabilities$0.3B$0.3B$0.4B$0.4B$0.3B$0.4B$0.3B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$0.2B$0.2B$0.3B$0.5B$0.6B$0.7B$0.6B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Operating Cash Flow$-0.0B$-0.1B$-0.2B$-0.2B$-0.2B$-0.1B$0.2B
Investing Cash Flow$0.0B$0.1B$0.1B$0.0B$0.2B$-0.1B$-0.5B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.1B$0.0B$0.3B$0.3B
← Companies